{"entity":{"id":"nct07597629","kind":"trial","name":"A Clinical Study of SYS6023 Combination Therapy for Advanced Breast Cancer","aka":[],"tldr":"A phase 2 trial of SYS6023 and KN026 in advanced solid tumours, run by CSPC Megalith Biopharmaceutical Co.,Ltd., now recruiting.","summary":"A Clinical Study of SYS6023 Combination Therapy for Advanced Breast Cancer is a phase 2 interventional study registered as NCT07597629 by CSPC Megalith Biopharmaceutical Co.,Ltd., with 36 participants planned, started 2026-05-25 and due to reach its primary completion in 2027-11-30. Interventions recorded: SYS6023 and KN026.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07597629","url":"https://clinicaltrials.gov/study/NCT07597629"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["sys6023","kn026"],"companies":["cspc"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07597629","phase":"2","setting":"A Phase II Clinical Study Evaluating the Efficacy and Safety of SYS6023 Combination Therapy for Unresectable Locally Advanced or Metastatic Breast Cancer","sponsor":"CSPC Megalith Biopharmaceutical Co.,Ltd.","enrolled":36,"outcomes":[]},"route":"/trials/nct07597629/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"drug":[{"id":"kn026","kind":"drug","name":"KN026","route":"/drugs/kn026/"},{"id":"sys6023","kind":"drug","name":"SYS6023","route":"/drugs/sys6023/"}],"company":[{"id":"cspc","kind":"company","name":"CSPC Pharmaceutical Group","route":"/companies/cspc/"}]}}